The Liver Meeting 2024 - Debrief Sessions - Spanish-Alcohol-Associated Liver Disease Debrief Session

Video Transcription

Video Summary

Dr. Juan Pablo Arab presented recent developments in alcohol-associated liver disease (ALD) at a conference, focusing on both preclinical and clinical findings. He emphasized the importance of the gut-liver axis and discussed how certain interventions, like GLP-1 receptor agonists, have shown promise in reducing liver injury in ALD models. He highlighted research examining the role of neutrophils and mitochondrial dysfunction in ALD, identifying potential therapeutic targets. Clinically, Dr. Arab discussed the interplay between metabolic factors and ALD outcomes, noting that metabolic features such as diabetes influence fibrosis progression. The challenge of alcohol use disorder (AUD) in ALD patients remains significant, with trends showing increased AUD rates, especially in older U.S. populations. Innovative approaches, including pharmacological treatments and the integration of hepatology with addiction services, were explored to improve patient outcomes. Lastly, novel tools like virtual reality for cognitive behavioral therapy in this context were introduced as potential interventions.

Keywords

alcohol-associated liver disease

gut-liver axis

GLP-1 receptor agonists

metabolic factors

alcohol use disorder

virtual reality therapy